Skip to main content
Premium Trial:

Request an Annual Quote

ImmusanT Nabs $12M Investment to Support Celiac Disease CDx and Immunotherapy

NEW YORK (GenomeWeb) – ImmusanT today announced it has raised $12 million in Series B financing from Vatera Healthcare Partners to continue developing Nexvax2, an immunotherapy for celiac disease, as well as a companion diagnostic to pair with the treatment and a standalone blood-based diagnostic.

The Cambridge, Mass.-based firm will continue to develop its whole-blood functional T-cell test as both a companion diagnostic to identify patients most likely to respond to Nexvax2 and as a standalone test.

Nexvax2 is an adjuvant-free, disease-modifying immunotherapy for celiac disease that reprograms a patient's immune system to tolerate gluten in the diet. It is comprised solely of three gluten-derived peptides in saline that are responsible for the immune reaction that causes celiac disease. ImmusanT recently completed two Phase 1b studies to demonstrate safety, tolerability, and bioactivity of Nexvax2, and Phase II trials will begin in early 2015, the firm said in a statement.

The funding follows $20 million that ImmusanT received from Vatera in 2011 for the development of celiac diagnostic tools.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.